Story
ExxonMobil Options Market Braces for 3.3% Post-Earnings Stock Move
Summary
Options traders are pricing in a potential 3.3% swing for ExxonMobil's stock following its July 31 earnings release, according to Bloomberg data. A review of past reports shows the stock has exceeded the market's implied move in three of the last eight quarters.
The options market is anticipating a notable price swing for ExxonMobil (NYSE: XOM) shares following its upcoming earnings announcement. Traders are pricing in a potential move of 3.3% in either direction after the energy giant reports its financial results before the market opens on July 31, according to data compiled by Bloomberg.
Gauging Potential Volatility
This implied volatility figure is derived from the pricing of options contracts and serves as a key indicator of market expectations for the stock's reaction to the new financial data. It reflects the consensus forecast for how much the stock might move but does not predict the direction of the change.
Investors and analysts will be closely watching ExxonMobil's report for insights into production levels, downstream refining margins, and the impact of recent commodity price fluctuations on its profitability. The company's guidance on future capital expenditures and shareholder returns will also be a critical focus.
AdHistorical Performance vs. Expectations
A review of the company's last eight earnings reports reveals a mixed record of actual price moves compared to what the options market had predicted. The stock's post-earnings move has exceeded the implied volatility on three of those eight occasions.
For instance, following its January 30 earnings release, the stock experienced a 5.8% price change, significantly outpacing the 2.0% move implied by options at the time. Conversely, after the most recent report on May 1, the stock moved just 1.5%, which was less than the 2.5% volatility priced in by the market.
Read next
More on Stocks
Erste Group Bids for Majority Stake in Erste Bank Polska With Tender Offer
The Austrian lender plans to launch a cash tender offer for up to 26% of its Polish subsidiary at a discount to the market price, aiming to secure a controlling interest.
Mirum Pharmaceuticals Wins FDA Approval for Rare Bone Disorder Drug Atebrioz
The U.S. Food and Drug Administration has approved Mirum Pharmaceuticals' drug, Atebrioz (zilurgisertib), for treating fibrodysplasia ossificans progressiva (FOP), a rare genetic condition causing abnormal bone growth.
Rithm Capital Credit Rating Raised to 'B+' by S&P on Successful Diversification
S&P Global Ratings upgraded Rithm Capital's credit rating to 'B+' with a stable outlook, crediting the firm's significant expansion into asset management and private credit, which has reduced its reliance on traditional mortgage finance.
US Appeals Court Rules States Can Regulate Kalshi's Prediction Markets
A federal appeals court has ruled that states can regulate Kalshi's event contracts under local gambling laws, a decision that rejects the prediction market's bid for exclusive federal oversight by the CFTC.